Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neladenoson bialanate
- Development stage
- Phase 2
- Lead developer
- Bayer HealthCare Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Neladenoson bialanate is a first-in-class, orally administered, small molecule that acts as a partial and highly selective agonist of the adenosine A1 receptor. It was developed for the treatment of chronic heart failure, including both heart failure with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). The drug was designed to maintain the cardioprotective effects of adenosine while minimizing side effects associated with full agonists. Clinical trials included phase 2 studies in patients with chronic heart failure; however, development was discontinued after these studies did not demonstrate significant clinical benefit[1][3][4][6].
- Other names
- neladenoson bialanate
02
Targets
ADORA1 (Adenosine receptor A1 subtype)
Beyond the preview
Go deeper on neladenoson bialanate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neladenoson bialanate.